5-methyltetrahydrofolate-homocysteine methyltransferaseGenealiases: HMAG · MS · cblG
Q-omics provides the consensus-scored MTR profile across patient tissues and cancer cell-line models. MTR expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTR is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, MTR protein abundance shows 24,943 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where MTR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTR survival associations across molecular data types. MTR RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTR RNA expression–survival associations across cancer types. High MTR expression shows unfavorable associations in ACC, THCA, MESO and LGG, but favorable associations in KIRC and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTR RNA expression.
This table summarizes MTR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MTR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTR shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in HNSC, LIHC and COAD. The HNSC box plot shows higher MTR RNA expression in tumor versus normal tissue (log2 FC = +0.888, t-test p < 0.001).
This table shows molecular features associated with MTR in patient tissues and cancer cell lines. In patient samples, MTR shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MTR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
